[Preserving future therapy options. Darunavir--the protease inhibitor for various patient groups].
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D018791:CD4 Lymphocyte Count; D002986:Clinical Trials as Topic; D000069454:Darunavir; D018432:Drug Resistance, Multiple / Q000187:drug effects*; D024882:Drug Resistance, Viral / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D061466:Lopinavir; D011744:Pyrimidinones / Q000009:adverse effects / Q000627:therapeutic use; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D019562:Viral Load
D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D013449:Sulfonamides; D061466:Lopinavir; D000069454:Darunavir